German Society of Nuclear Medicine procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals (09/2025) S1-Handlungsempfehlung der Deutschen Gesellschaft für Nuklearmedizin zur Durchführung von Hirnperfusions-SPECT-Untersuchungen mit 99mTc-markierten Radiopharmaka (Stand 09/2025)

Buchert R, Meyer PT, Albert NL, Barthel H, Boecker H, Bouter C, Brendel M, Brumberg J, Coenen HH, Drzezga A, Gründer G, Grünwald F, Hesse S, Kuwert T, la Fougère C, Lange C, Lohmann P, Menzel C, Miederer I, Neumaier B, Rominger A, Schmitz CN, Schreckenberger M, Yakushev I, Kranert WT (2026)


Publication Type: Journal article

Publication year: 2026

Journal

DOI: 10.1055/a-2821-9573

Abstract

This procedure guideline for brain perfusion SPECT is intended to support the planning, execution, quality control, evaluation and reporting of brain perfusion SPECT studies using the 99 mTc-labelled radiopharmaceuticals [99 mTc]Tc-HMPAO and [99 mTc]Tc-ECD. It is an update and expansion built on the 2019 version of the procedure guideline. It was developed through an informal process as a consensus of the Neuroimaging Working Group of the German Society of Nuclear Medicine. It is intended for use by physicians and physical-technical staff (technologists, physicists) working in nuclear medicine.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Buchert, R., Meyer, P.T., Albert, N.L., Barthel, H., Boecker, H., Bouter, C.,... Kranert, W.T. (2026). German Society of Nuclear Medicine procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals (09/2025) S1-Handlungsempfehlung der Deutschen Gesellschaft für Nuklearmedizin zur Durchführung von Hirnperfusions-SPECT-Untersuchungen mit 99mTc-markierten Radiopharmaka (Stand 09/2025). Nuklearmedizin-Nuclear Medicine. https://doi.org/10.1055/a-2821-9573

MLA:

Buchert, Ralph, et al. "German Society of Nuclear Medicine procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals (09/2025) S1-Handlungsempfehlung der Deutschen Gesellschaft für Nuklearmedizin zur Durchführung von Hirnperfusions-SPECT-Untersuchungen mit 99mTc-markierten Radiopharmaka (Stand 09/2025)." Nuklearmedizin-Nuclear Medicine (2026).

BibTeX: Download